
Leading U.S. obesity specialists anticipate that Eli Lilly's weight-loss drug Zepbound will provide similar heart benefits as Novo Nordisk's Wegovy, belonging to the same class of medicines. Five senior physicians suggest Wegovy may not hold a significant advantage in cardiovascular benefits. Although Lilly's cardiovascular data is years away, both drugs, GLP-1 agonists designed for type 2 diabetes, are expected to offer comparable heart protection. Zepbound, recently FDA-approved, is set to compete with Wegovy, which reduced heart-related risks by 20% in trials. Doctors favour Zepbound due to greater weight loss (20% vs Wegovy's 15%).
Like
Save
Share